Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1792, Issue 7, 2009, Pages 651-663

  Banerjee, Rebecca ^a   Starkov, Anatoly A ^a   Beal, M Flint ^a   Thomas, Bobby ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

synuclein; DJ 1; Electron transport chain; LRRK2; Mitochondrial DNA; Mitochondrial dysfunction; Parkin; Permeability transition pore; PINK1

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CASPASE 3; CREATINE; CYTOCHROME C OXIDASE; DJ 1 PROTEIN; DOPAMINE TRANSPORTER; GLUTATHIONE; HERBICIDE; LEUCINE RICH REPEAT KINASE 2; LEVODOPA; MANEB; MITOCHONDRIAL DNA; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NEUROLEPTIC AGENT; PARAQUAT; PARKIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PESTICIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; SERINE PROTEINASE OMI; SUCCINATE DEHYDROGENASE (UBIQUINONE); SUPEROXIDE DISMUTASE; TYROSINE 3 MONOOXYGENASE; UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE; UNINDEXED DRUG;

AGING; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG TARGETING; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; INCIDENCE; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL PERMEABILITY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; HUMANS; MITOCHONDRIA; MUTATION; PARKINSON DISEASE;

EID: 68649108355     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.11.007     Document Type: Review

References (228)

1. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58 (2005) 495-505
2. Forno L.S. Neuropathology of Parkinson's disease. J. Neuropathol. Exp. Neurol. 55 (1996) 259-272
3. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 339 (1998) 1044-1053
4. Lang A.E., and Lozano A.M. Parkinson's disease. Second of two parts. N. Engl. J. Med. 339 (1998) 1130-1143
5. Savitt J.M., Dawson V.L., and Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116 (2006) 1744-1754
6. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
7. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., and Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. U. S. A. 80 (1983) 4546-4550
8. Heikkila R.E., Manzino L., Cabbat F.S., and Duvoisin R.C. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrostriatal pathway in mice. Neurosci. Lett. 58 (1985) 133-137
9. Kopin I.J., and Markey S.P. MPTP toxicity: implications for research in Parkinson's disease. Annu. Rev. Neurosci. 11 (1988) 81-96
10. Chiba K., Trevor A., and Castagnoli Jr. N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120 (1984) 574-578
11. Heikkila R.E., Manzino L., Cabbat F.S., and Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311 (1984) 467-469
12. Ramsay R.R., Salach J.I., and Singer T.P. Uptake of the neurotoxin 1-methyl-4-phenylpyridine (MPP+) by mitochondria and its relation to the inhibition of the mitochondrial oxidation of NAD+-linked substrates by MPP+. Biochem. Biophys. Res. Commun. 134 (1986) 743-748
13. Nicklas W.J., Vyas I., and Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36 (1985) 2503-2508
14. Ramsay R.R., Salach J.I., Dadgar J., and Singer T.P. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem. Biophys. Res. Commun. 135 (1986) 269-275
15. Mizuno Y., Sone N., Suzuki K., and Saitoh T. Studies on the toxicity of 1-methyl-4-phenylpyridinium ion (MPP+) against mitochondria of mouse brain. J. Neurol. Sci. 86 (1988) 97-110
16. Mizuno Y., Suzuki K., Sone N., and Saitoh T. Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo. Neurosci. Lett. 91 (1988) 349-353
17. Javitch J.A., D'Amato R.J., Strittmatter S.M., and Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 2173-2177
18. Frankhauser P., Grimmer Y., Bugert P., Deuschle M., Schmidt M., and Schloss P. Characterization of the neuronal dopamine transporter DAT in human blood platelets. Neurosci. Lett. 399 (2006) 197-201
19. Buckman T.D., Chang R., Sutphin M.S., and Eiduson S. Interaction of 1-methyl-4-phenylpyridinium ion with human platelets. Biochem. Biophys. Res. Commun. 151 (1988) 897-904
20. Yoshino H., Nakagawa-Hattori Y., Kondo T., and Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J. Neural Transm., Parkinson's Dis. Dement. Sect. 4 (1992) 27-34
21. Haas R.H., Nasirian F., Nakano K., Ward D., Pay M., Hill R., and Shults C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37 (1995) 714-722
22. Benecke R., Strumper P., and Weiss H. Electron transfer complexes I and IV of platelets are abnormal in Parkinson's disease but normal in Parkinson-plus syndromes. Brain 116 Pt 6 (1993) 1451-1463
23. Parker Jr. W.D., Boyson S.J., and Parks J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26 (1989) 719-723
24. Burkhardt C., Kelly J.P., Lim Y.H., Filley C.M., and Parker Jr. W.D. Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol. 33 (1993) 512-517
25. Przedborski S., Jackson-Lewis V., Muthane U., Jiang H., Ferreira M., Naini A.B., and Fahn S. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann. Neurol. 34 (1993) 715-723
26. Swerdlow R.H., Parks J.K., Cassarino D.S., Binder D.R., Bennett Jr. J.P., Di Iorio G., Golbe L.I., and Parker Jr. W.D. Biochemical analysis of cybrids expressing mitochondrial DNA from Contursi kindred Parkinson's subjects. Exp. Neurol. 169 (2001) 479-485
27. Aomi Y., Chen C.S., Nakada K., Ito S., Isobe K., Murakami H., Kuno S.Y., Tawata M., Matsuoka R., Mizusawa H., and Hayashi J.I. Cytoplasmic transfer of platelet mtDNA from elderly patients with Parkinson's disease to mtDNA-less HeLa cells restores complete mitochondrial respiratory function. Biochem. Biophys. Res. Commun. 280 (2001) 265-273
28. Blake C.I., Spitz E., Leehey M., Hoffer B.J., and Boyson S.J. Platelet mitochondrial respiratory chain function in Parkinson's disease. Mov. Disord. 12 (1997) 3-8
29. Mann V.M., Cooper J.M., Krige D., Daniel S.E., Schapira A.H., and Marsden C.D. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115 Pt 2 (1992) 333-342
30. Bravi D., Anderson J.J., Dagani F., Davis T.L., Ferrari R., Gillespie M., and Chase T.N. Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease. Mov. Disord. 7 (1992) 228-231
31. Hanagasi H.A., Ayribas D., Baysal K., and Emre M. Mitochondrial complex I, II/III, and IV activities in familial and sporadic Parkinson's disease. Int. J. Neurosci. 115 (2005) 479-493
32. Schapira A.H., Mann V.M., Cooper J.M., Dexter D., Daniel S.E., Jenner P., Clark J.B., and Marsden C.D. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J. Neurochem. 55 (1990) 2142-2145
33. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1 (1989) 1269
34. Janetzky Z.B., Hauck S., Youdim M.B., Riederer P., Jellinger K., Pantucek F., Zochling R., Boissl K.W., and Reichmann H. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci. Lett. 169 (1994) 126-128
35. Parker Jr. W.D., Parks J.K., and Swerdlow R.H. Complex I deficiency in Parkinson's disease frontal cortex. Brain Res. 1189 (2008) 215-218
36. Keeney P.M., Xie J., Capaldi R.A., and Bennett Jr. J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26 (2006) 5256-5264
37. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., and Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163 (1989) 1450-1455
38. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54 (1990) 823-827
39. Cardellach F., Marti M.J., Fernandez-Sola J., Marin C., Hoek J.B., Tolosa E., and Urbano-Marquez A. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 43 (1993) 2258-2262
40. Blin O., Desnuelle C., Rascol O., Borg M., Peyro Saint Paul H., Azulay J.P., Bille F., Figarella D., Coulom F., Pellissier J.F., et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. J. Neurol. Sci. 125 (1994) 95-101
41. Bindoff L.A., Birch-Machin M.A., Cartlidge N.E., Parker Jr. W.D., and Turnbull D.M. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson's disease. J. Neurol. Sci. 104 (1991) 203-208
42. DiDonato S., Zeviani M., Giovannini P., Savarese N., Rimoldi M., Mariotti C., Girotti F., and Caraceni T. Respiratory chain and mitochondrial DNA in muscle and brain in Parkinson's disease patients. Neurology 43 (1993) 2262-2268
43. Reichmann H., Janetzky B., Bischof F., Seibel P., Schols L., Kuhn W., and Przuntek H. Unaltered respiratory chain enzyme activity and mitochondrial DNA in skeletal muscle from patients with idiopathic Parkinson's syndrome. Eur. Neurol. 34 (1994) 263-267
44. Shinde S., and Pasupathy K. Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from patients with Parkinson's disease: preliminary study. Neurol. India 54 (2006) 390-393
45. Martin M.A., Molina J.A., Jimenez-Jimenez F.J., Benito-Leon J., Orti-Pareja M., Campos Y., and Arenas J. Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from untreated Parkinson's disease patients. Grupo-Centro de Trastornos del Movimiento. Neurology 46 (1996) 1343-1346
46. Elbaz A., and Tranchant C. Epidemiologic studies of environmental exposures in Parkinson's disease. J. Neurol. Sci. 262 (2007) 37-44
47. Tanner C.M., and Ben-Shlomo Y. Epidemiology of Parkinson's disease. Adv. Neurol. 80 (1999) 153-159
48. Fung H.C., Scholz S., Matarin M., Simon-Sanchez J., Hernandez D., Britton A., Gibbs J.R., Langefeld C., Stiegert M.L., Schymick J., Okun M.S., Mandel R.J., Fernandez H.H., Foote K.D., Rodriguez R.L., Peckham E., De Vrieze F.W., Gwinn-Hardy K., Hardy J.A., and Singleton A. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 5 (2006) 911-916
49. Hatcher J.M., Pennell K.D., and Miller G.W. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol. Sci. 29 (2008) 322-329
50. Liou H.H., Tsai M.C., Chen C.J., Jeng J.S., Chang Y.C., Chen S.Y., and Chen R.C. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 48 (1997) 1583-1588
51. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., and Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311 (1984) 464-467
52. Hertzman C., Wiens M., Bowering D., Snow B., and Calne D. Parkinson's disease: a case-control study of occupational and environmental risk factors. Am. J. Ind. Med. 17 (1990) 349-355
53. Sechi G.P., Agnetti V., Piredda M., Canu M., Deserra F., Omar H.A., and Rosati G. Acute and persistent parkinsonism after use of diquat. Neurology 42 (1992) 261-263
54. Thiruchelvam M., McCormack A., Richfield E.K., Baggs R.B., Tank A.W., Di Monte D.A., and Cory-Slechta D.A. Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur. J. Neurosci. 18 (2003) 589-600
55. Brown T.P., Rumsby P.C., Capleton A.C., Rushton L., and Levy L.S. Pesticides and Parkinson's disease - is there a link?. Environ. Health Perspect. 114 (2006) 156-164
56. Manning-Bog A.B., McCormack A.L., Li J., Uversky V.N., Fink A.L., and Di Monte D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J. Biol. Chem. 277 (2002) 1641-1644
57. Richardson J.R., Quan Y., Sherer T.B., Greenamyre J.T., and Miller G.W. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicol. Sci. 88 (2005) 193-201
58. Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69 (1997) 1322-1325
59. Bonneh-Barkay D., Reaney S.H., Langston W.J., and Di Monte D.A. Redox cycling of the herbicide paraquat in microglial cultures. Brain Res. Mol. Brain Res. 134 (2005) 52-56
60. Winterbourn C.C., and Sutton H.C. Hydroxyl radical production from hydrogen peroxide and enzymatically generated paraquat radicals: catalytic requirements and oxygen dependence. Arch. Biochem. Biophys. 235 (1984) 116-126
61. Ramachandiran S., Hansen J.M., Jones D.P., Richardson J.R., and Miller G.W. Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation. Toxicol. Sci. 95 (2007) 163-171
62. Castello P.R., Drechsel D.A., and Patel M. Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain. J. Biol. Chem. 282 (2007) 14186-14193
63. Thiruchelvam M., Richfield E.K., Baggs R.B., Tank A.W., and Cory-Slechta D.A. The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease. J. Neurosci. 20 (2000) 9207-9214
64. Thiruchelvam M., Richfield E.K., Goodman B.M., Baggs R.B., and Cory-Slechta D.A. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology 23 (2002) 621-633
65. Meco G., Bonifati V., Vanacore N., and Fabrizio E. Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). Scand. J. Work, Environ. & Health 20 (1994) 301-305
66. Ferraz H.B., Bertolucci P.H., Pereira J.S., Lima J.G., and Andrade L.A. Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication. Neurology 38 (1988) 550-553
67. Fitsanakis V.A., Amarnath V., Moore J.T., Montine K.S., Zhang J., and Montine T.J. Catalysis of catechol oxidation by metal-dithiocarbamate complexes in pesticides. Free Radic. Biol. Med. 33 (2002) 1714-1723
68. Pesah Y., Pham T., Burgess H., Middlebrooks B., Verstreken P., Zhou Y., Harding M., Bellen H., and Mardon G. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131 (2004) 2183-2194
69. Fei Q., McCormack A.L., Di Monte D.A., and Ethell D.W. Paraquat neurotoxicity is mediated by a Bak-dependent mechanism. J. Biol. Chem. 283 (2008) 3357-3364
70. Fei Q., and Ethell D.W. Maneb potentiates paraquat neurotoxicity by inducing key Bcl-2 family members. J. Neurochem. 105 6 (2008) 2091-2097
71. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
72. Alam M., and Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 136 (2002) 317-324
73. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 (2003) 9-16
74. Andreyev A.Y., Kushnareva Y.E., and Starkov A.A. Mitochondrial metabolism of reactive oxygen species. Biochemistry (Mosc.) 70 (2005) 200-214
75. Ma X., Kalakonda S., Srinivasula S.M., Reddy S.P., Platanias L.C., and Kalvakolanu D.V. GRIM-19 associates with the serine protease HtrA2 for promoting cell death. Oncogene 26 (2007) 4842-4849
76. Plun-Favreau H., Klupsch K., Moisoi N., Gandhi S., Kjaer S., Frith D., Harvey K., Deas E., Harvey R.J., McDonald N., Wood N.W., Martins L.M., and Downward J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat. Cell Biol. 9 (2007) 1243-1252
77. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003) 10756-10764
78. Choi W.S., Kruse S.E., Palmiter R.D., and Xia Z. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 15136-15141
79. Marella M., Seo B.B., Nakamaru-Ogiso E., Greenamyre J.T., Matsuno-Yagi A., and Yagi T. Protection by the NDI1 gene against neurodegeneration in a rotenone rat model of Parkinson's disease. PLoS ONE 3 (2008) e1433
80. Richter C., Park J.W., and Ames B.N. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. U. S. A. 85 (1988) 6465-6467
81. Ozawa T. Oxidative damage and fragmentation of mitochondrial DNA in cellular apoptosis. Biosci. Rep. 17 (1997) 237-250
82. Swerdlow R.H., Parks J.K., Miller S.W., Tuttle J.B., Trimmer P.A., Sheehan J.P., Bennett Jr. J.P., Davis R.E., and Parker Jr. W.D. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann. Neurol. 40 (1996) 663-671
83. Gu M., Cooper J.M., Taanman J.W., and Schapira A.H. Mitochondrial DNA transmission of the mitochondrial defect in Parkinson's disease. Ann. Neurol. 44 (1998) 177-186
84. Sheehan J.P., Swerdlow R.H., Parker W.D., Miller S.W., Davis R.E., and Tuttle J.B. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J. Neurochem. 68 (1997) 1221-1233
85. Swerdlow R.H., Parks J.K., Davis II J.N., Cassarino D.S., Trimmer P.A., Currie L.J., Dougherty J., Bridges W.S., Bennett Jr. J.P., Wooten G.F., and Parker W.D. Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann. Neurol. 44 (1998) 873-881
86. Wooten G.F., Currie L.J., Bennett J.P., Harrison M.B., Trugman J.M., and Parker Jr. W.D. Maternal inheritance in Parkinson's disease. Ann. Neurol. 41 (1997) 265-268
87. Thyagarajan D., Bressman S., Bruno C., Przedborski S., Shanske S., Lynch T., Fahn S., and DiMauro S. A novel mitochondrial 12SrRNA point mutation in parkinsonism, deafness, and neuropathy. Ann. Neurol. 48 (2000) 730-736
88. Simon D.K., Pulst S.M., Sutton J.P., Browne S.E., Beal M.F., and Johns D.R. Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation. Neurology 53 (1999) 1787-1793
89. Simon D.K., Mayeux R., Marder K., Kowall N.W., Beal M.F., and Johns D.R. Mitochondrial DNA mutations in complex I and tRNA genes in Parkinson's disease. Neurology 54 (2000) 703-709
90. Vives-Bauza C., Andreu A.L., Manfredi G., Beal M.F., Janetzky B., Gruenewald T.H., and Lin M.T. Sequence analysis of the entire mitochondrial genome in Parkinson's disease. Biochem. Biophys. Res. Commun. 290 (2002) 1593-1601
91. Parker Jr. W.D., and Parks J.K. Mitochondrial ND5 mutations in idiopathic Parkinson's disease. Biochem. Biophys. Res. Commun. 326 (2005) 667-669
92. Ruiz-Pesini E., Mishmar D., Brandon M., Procaccio V., and Wallace D.C. Effects of purifying and adaptive selection on regional variation in human mtDNA. Science 303 (2004) 223-226
93. van der Walt J.M., Nicodemus K.K., Martin E.R., Scott W.K., Nance M.A., Watts R.L., Hubble J.P., Haines J.L., Koller W.C., Lyons K., Pahwa R., Stern M.B., Colcher A., Hiner B.C., Jankovic J., Ondo W.G., Allen Jr. F.H., Goetz C.G., Small G.W., Mastaglia F., Stajich J.M., McLaurin A.C., Middleton L.T., Scott B.L., Schmechel D.E., Pericak-Vance M.A., and Vance J.M. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am. J. Hum. Genet. 72 (2003) 804-811
94. Pyle A., Foltynie T., Tiangyou W., Lambert C., Keers S.M., Allcock L.M., Davison J., Lewis S.J., Perry R.H., Barker R., Burn D.J., and Chinnery P.F. Mitochondrial DNA haplogroup cluster UKJT reduces the risk of PD. Ann. Neurol. 57 (2005) 564-567
95. Autere J., Moilanen J.S., Finnila S., Soininen H., Mannermaa A., Hartikainen P., Hallikainen M., and Majamaa K. Mitochondrial DNA polymorphisms as risk factors for Parkinson's disease and Parkinson's disease dementia. Hum. Genet. 115 (2004) 29-35
96. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., and Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat. Genet. 38 (2006) 515-517
97. Kraytsberg Y., Kudryavtseva E., McKee A.C., Geula C., Kowall N.W., and Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 38 (2006) 518-520
98. Kujoth G.C., Bradshaw P.C., Haroon S., and Prolla T.A. The role of mitochondrial DNA mutations in mammalian aging. PLoS Genet. 3 (2007) e24
99. Hattori N., Yoshino H., Tanaka M., Suzuki H., and Mizuno Y. Genotype in the 24-kDa subunit gene (NDUFV2) of mitochondrial complex I and susceptibility to Parkinson disease. Genomics 49 (1998) 52-58
100. Tanaka M. Mitochondrial genotypes and cytochrome b variants associated with longevity or Parkinson's disease. J. Neurol. 249 Suppl 2 (2002) II11-18
101. Alvarez V., Corao A.I., Sanchez-Ferrero E., De Mena L., Alonso-Montes C., Huerta C., Blazquez M., Ribacoba R., Guisasola L.M., Salvador C., Garcia-Castro M., and Coto E. Mitochondrial transcription factor A (TFAM) gene variation in Parkinson's disease. Neurosci. Lett. 432 (2008) 79-82
102. Belin A.C., Bjork B.F., Westerlund M., Galter D., Sydow O., Lind C., Pernold K., Rosvall L., Hakansson A., Winblad B., Nissbrandt H., Graff C., and Olson L. Association study of two genetic variants in mitochondrial transcription factor A (TFAM) in Alzheimer's and Parkinson's disease. Neurosci. Lett. 420 (2007) 257-262
103. Ekstrand M.I., Terzioglu M., Galter D., Zhu S., Hofstetter C., Lindqvist E., Thams S., Bergstrand A., Hansson F.S., Trifunovic A., Hoffer B., Cullheim S., Mohammed A.H., Olson L., and Larsson N.G. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 1325-1330
104. Filosto M., Mancuso M., Nishigaki Y., Pancrudo J., Harati Y., Gooch C., Mankodi A., Bayne L., Bonilla E., Shanske S., Hirano M., and DiMauro S. Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma. Arch. Neurol. 60 (2003) 1279-1284
105. Luoma P.T., Eerola J., Ahola S., Hakonen A.H., Hellstrom O., Kivisto K.T., Tienari P.J., and Suomalainen A. Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease. Neurology 69 (2007) 1152-1159
106. Mancuso M., Filosto M., Bellan M., Liguori R., Montagna P., Baruzzi A., DiMauro S., and Carelli V. POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness. Neurology 62 (2004) 316-318
107. Taanman J.W., and Schapira A.H. Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease. Neurosci. Lett. 376 (2005) 56-59
108. Hudson G., Schaefer A.M., Taylor R.W., Tiangyou W., Gibson A., Venables G., Griffiths P., Burn D.J., Turnbull D.M., and Chinnery P.F. Mutation of the linker region of the polymerase gamma-1 (POLG1) gene associated with progressive external ophthalmoplegia and Parkinsonism. Arch. Neurol. 64 (2007) 553-557
109. Davidzon G., Greene P., Mancuso M., Klos K.J., Ahlskog J.E., Hirano M., and DiMauro S. Early-onset familial parkinsonism due to POLG mutations. Ann. Neurol. 59 (2006) 859-862
110. Tiangyou W., Hudson G., Ghezzi D., Ferrari G., Zeviani M., Burn D.J., and Chinnery P.F. POLG1 in idiopathic Parkinson disease. Neurology 67 (2006) 1698-1700
111. Soane L., Kahraman S., Kristian T., and Fiskum G. Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders. J. Neurosci. Res. 85 (2007) 3407-3415
112. Youdim M.B., Bar Am O., Yogev-Falach M., Weinreb O., Maruyama W., Naoi M., and Amit T. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 79 (2005) 172-179
113. Friberg H., and Wieloch T. Mitochondrial permeability transition in acute neurodegeneration. Biochimie 84 (2002) 241-250
114. Norenberg M.D., and Rao K.V. The mitochondrial permeability transition in neurologic disease. Neurochem. Int. 50 (2007) 983-997
115. Haworth R.A., and Hunter D.R. The Ca2+-induced membrane transition in mitochondria. II. Nature of the Ca2+ trigger site. Arch. Biochem. Biophys. 195 (1979) 460-467
116. Zoratti M., and Szabo I. The mitochondrial permeability transition. Biochim. Biophys. Acta 1241 (1995) 139-176
117. Minamikawa T., Williams D.A., Bowser D.N., and Nagley P. Mitochondrial permeability transition and swelling can occur reversibly without inducing cell death in intact human cells. Exp. Cell Res. 246 (1999) 26-37
118. Lemasters J.J., Nieminen A.L., Qian T., Trost L.C., Elmore S.P., Nishimura Y., Crowe R.A., Cascio W.E., Bradham C.A., Brenner D.A., and Herman B. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. Biochim. Biophys. Acta 1366 (1998) 177-196
119. Huser J., Rechenmacher C.E., and Blatter L.A. Imaging the permeability pore transition in single mitochondria. Biophys. J. 74 (1998) 2129-2137
120. Di Lisa F., Menabo R., Canton M., Barile M., and Bernardi P. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J. Biol. Chem. 276 (2001) 2571-2575
121. Anderson M.F., and Sims N.R. The effects of focal ischemia and reperfusion on the glutathione content of mitochondria from rat brain subregions. J. Neurochem. 81 (2002) 541-549
122. Chalmers S., and Nicholls D.G. The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria. J. Biol. Chem. 278 (2003) 19062-19070
123. Kowaltowski A.J., Naia-da-Silva E.S., Castilho R.F., and Vercesi A.E. Ca2+-stimulated mitochondrial reactive oxygen species generation and permeability transition are inhibited by dibucaine or Mg2+. Arch. Biochem. Biophys. 359 (1998) 77-81
124. Panov A., Dikalov S., Shalbuyeva N., Hemendinger R., Greenamyre J.T., and Rosenfeld J. Species- and tissue-specific relationships between mitochondrial permeability transition and generation of ROS in brain and liver mitochondria of rats and mice. Am. J. Physiol., Cell Physiol. 292 (2007) C708-718
125. Frantseva M.V., Carlen P.L., and Perez Velazquez J.L. Dynamics of intracellular calcium and free radical production during ischemia in pyramidal neurons. Free Radic. Biol. Med. 31 (2001) 1216-1227
126. Leung A.W., and Halestrap A.P. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim. Biophys. Acta 1777 (2008) 946-952
127. Halestrap A.P., and Brennerb C. The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. Curr. Med. Chem. 10 (2003) 1507-1525
128. Bernardi P., Krauskopf A., Basso E., Petronilli V., Blachly-Dyson E., Di Lisa F., and Forte M.A. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J. 273 (2006) 2077-2099
129. Woodfield K., Ruck A., Brdiczka D., and Halestrap A.P. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. Biochem. J. 336 Pt 2 (1998) 287-290
130. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., Inohara H., Kubo T., and Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434 (2005) 652-658
131. Basso E., Fante L., Fowlkes J., Petronilli V., Forte M.A., and Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J. Biol. Chem. 280 (2005) 18558-18561
132. Schinzel A.C., Takeuchi O., Huang Z., Fisher J.K., Zhou Z., Rubens J., Hetz C., Danial N.N., Moskowitz M.A., and Korsmeyer S.J. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 12005-12010
133. Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., Brunskill E.W., Sayen M.R., Gottlieb R.A., Dorn G.W., Robbins J., and Molkentin J.D. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434 (2005) 658-662
134. Kokoszka J.E., Waymire K.G., Levy S.E., Sligh J.E., Cai J., Jones D.P., MacGregor G.R., and Wallace D.C. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature 427 (2004) 461-465
135. Frei B., and Richter C. N-methyl-4-phenylpyridine (MMP+) together with 6-hydroxydopamine or dopamine stimulates Ca2+ release from mitochondria. FEBS Lett. 198 (1986) 99-102
136. Cassarino D.S., Parks J.K., Parker Jr. W.D., and Bennett Jr. J.P. The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim. Biophys. Acta 1453 (1999) 49-62
137. Packer M.A., Miesel R., and Murphy M.P. Exposure to the parkinsonian neurotoxin 1-methyl-4-phenylpyridinium (MPP+) and nitric oxide simultaneously causes cyclosporin A-sensitive mitochondrial calcium efflux and depolarisation. Biochem. Pharmacol. 51 (1996) 267-273
138. Kristal B.S., Conway A.D., Brown A.M., Jain J.C., Ulluci P.A., Li S.W., and Burke W.J. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic. Biol. Med. 30 (2001) 924-931
139. Stavrovskaya I.G., Narayanan M.V., Zhang W., Krasnikov B.F., Heemskerk J., Young S.S., Blass J.P., Brown A.M., Beal M.F., Friedlander R.M., and Kristal B.S. Clinically approved heterocyclics act on a mitochondrial target and reduce stroke-induced pathology. J. Exp. Med. 200 (2004) 211-222
140. Cleren C., Starkov A.A., Calingasan N.Y., Lorenzo B.J., Chen J., and Beal M.F. Promethazine protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. Neurobiol. Dis. 20 (2005) 701-708
141. Perier C., Bove J., Wu D.C., Dehay B., Choi D.K., Jackson-Lewis V., Rathke-Hartlieb S., Bouillet P., Strasser A., Schulz J.B., Przedborski S., and Vila M. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 8161-8166
142. Fontaine E., and Bernardi P. Progress on the mitochondrial permeability transition pore: regulation by complex I and ubiquinone analogs. J. Bioenerg. Biomembranes 31 (1999) 335-345
143. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
144. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
145. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., and de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004) 164-173
146. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
147. Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., and Lee M.K. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 26 (2006) 41-50
148. Thomas B., and Beal M.F. Parkinson's disease. Hum. Mol. Genet. 16 Spec. No. 2 (2007) R183-194
149. Norris E.H., Uryu K., Leight S., Giasson B.I., Trojanowski J.Q., and Lee V.M. Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. Am. J. Pathol. 170 (2007) 658-666
150. Klivenyi P., Siwek D., Gardian G., Yang L., Starkov A., Cleren C., Ferrante R.J., Kowall N.W., Abeliovich A., and Beal M.F. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 21 (2006) 541-548
151. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., and Sudhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 3413-3418
152. Thomas B., von Coelln R., Mandir A.S., Trinkaus D.B., Farah M.H., Leong Lim K., Calingasan N.Y., Flint Beal M., Dawson V.L., and Dawson T.M. MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol. Dis. 26 (2007) 312-322
153. Lee H.J., Shin S.Y., Choi C., Lee Y.H., and Lee S.J. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 277 (2002) 5411-5417
154. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A., Dawson V.L., Dawson T.M., and Ross C.A. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum. Mol. Genet. 10 (2001) 919-926
155. Poon H.F., Frasier M., Shreve N., Calabrese V., Wolozin B., and Butterfield D.A. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice-a model of familial Parkinson's disease. Neurobiol. Dis. 18 (2005) 492-498
156. Xun Z., Sowell R.A., Kaufman T.C., and Clemmer D.E. Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease. Mol. Cell. Proteomics 7 (2008) 1191-1203
157. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., and Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J. Biol. Chem. 283 (2008) 9089-9100
158. Cole N.B., Dieuliis D., Leo P., Mitchell D.C., and Nussbaum R.L. Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp. Cell Res. 314 (2008) 2076-2089
159. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
160. Lucking C.B., Durr A., Bonifati V., Vaughan J., De Michele G., Gasser T., Harhangi B.S., Meco G., Denefle P., Wood N.W., Agid Y., and Brice A. Association between early-onset Parkinson's disease and mutations in the parkin gene. N. Engl. J. Med. 342 (2000) 1560-1567
161. Farrer M., Chan P., Chen R., Tan L., Lincoln S., Hernandez D., Forno L., Gwinn-Hardy K., Petrucelli L., Hussey J., Singleton A., Tanner C., Hardy J., and Langston J.W. Lewy bodies and parkinsonism in families with parkin mutations. Ann. Neurol. 50 (2001) 293-300
162. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., and Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25 (2000) 302-305
163. Dawson T.M. Parkin and defective ubiquitination in Parkinson's disease. J. Neural. Transm., Suppl. (2006) 209-213
164. Moore D.J. Parkin: a multifaceted ubiquitin ligase. Biochem. Soc. Trans. 34 (2006) 749-753
165. Mukhopadhyay D., and Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 315 (2007) 201-205
166. Fallon L., Belanger C.M., Corera A.T., Kontogiannea M., Regan-Klapisz E., Moreau F., Voortman J., Haber M., Rouleau G., Thorarinsdottir T., Brice A., van Bergen En Henegouwen P.M., and Fon E.A. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nat. Cell Biol. 8 (2006) 834-842
167. Darios F., Corti O., Lucking C.B., Hampe C., Muriel M.P., Abbas N., Gu W.J., Hirsch E.C., Rooney T., Ruberg M., and Brice A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 12 (2003) 517-526
168. Stichel C.C., Augustin M., Kuhn K., Zhu X.R., Engels P., Ullmer C., and Lubbert H. Parkin expression in the adult mouse brain. Eur. J. Neurosci. 12 (2000) 4181-4194
169. Kuroda Y., Mitsui T., Kunishige M., Shono M., Akaike M., Azuma H., and Matsumoto T. Parkin enhances mitochondrial biogenesis in proliferating cells. Hum. Mol. Genet. 15 (2006) 883-895
170. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., and Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279 (2004) 18614-18622
171. Moore D.J., and Dawson T.M. Value of genetic models in understanding the cause and mechanisms of Parkinson's disease. Curr. Neurol. Neurosci. Rep. 8 (2008) 288-296
172. Whitworth A.J., Wes P.D., and Pallanck L.J. Drosophila models pioneer a new approach to drug discovery for Parkinson's disease. Drug Discov. Today 11 (2006) 119-126
173. Yang H., Zhou H.Y., Li B., Niu G.Z., and Chen S.D. Downregulation of parkin damages antioxidant defenses and enhances proteasome inhibition-induced toxicity in PC12 cells. J. Neuroimmune Pharmacol. 2 (2007) 276-283
174. Whitworth A.J., Theodore D.A., Greene J.C., Benes H., Wes P.D., and Pallanck L.J. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 8024-8029
175. Trinh K., Moore K., Wes P.D., Muchowski P.J., Dey J., Andrews L., and Pallanck L.J. Induction of the phase II detoxification pathway suppresses neuron loss in Drosophila models of Parkinson's disease. J. Neurosci. 28 (2008) 465-472
176. Hasegawa T., Treis A., Patenge N., Fiesel F.C., Springer W., and Kahle P.J. Parkin protects against tyrosinase-mediated dopamine neurotoxicity by suppressing stress-activated protein kinase pathways. J. Neurochem. 105 (2008) 1700-1715
177. Cha G.H., Kim S., Park J., Lee E., Kim M., Lee S.B., Kim J.M., Chung J., and Cho K.S. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10345-10350
178. Casarejos M.J., Menendez J., Solano R.M., Rodriguez-Navarro J.A., Garcia de Yebenes J., and Mena M.A. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J. Neurochem. 97 (2006) 934-946
179. Rosen K.M., Veereshwarayya V., Moussa C.E., Fu Q., Goldberg M.S., Schlossmacher M.G., Shen J., and Querfurth H.W. Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. J. Biol. Chem. 281 (2006) 12809-12816
180. Muftuoglu M., Elibol B., Dalmizrak O., Ercan A., Kulaksiz G., Ogus H., Dalkara T., and Ozer N. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov. Disord. 19 (2004) 544-548
181. Stichel C.C., Zhu X.R., Bader V., Linnartz B., Schmidt S., and Lubbert H. Mono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage. Hum. Mol. Genet. 16 (2007) 2377-2393
182. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., Yoo S.J., Hay B.A., and Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441 (2006) 1162-1166
183. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., Bae E., Kim J., Shong M., Kim J.M., and Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441 (2006) 1157-1161
184. Yang Y., Gehrke S., Imai Y., Huang Z., Ouyang Y., Wang J.W., Yang L., Beal M.F., Vogel H., and Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 10793-10798
185. Exner N., Treske B., Paquet D., Holmstrom K., Schiesling C., Gispert S., Carballo-Carbajal I., Berg D., Hoepken H.H., Gasser T., Kruger R., Winklhofer K.F., Vogel F., Reichert A.S., Auburger G., Kahle P.J., Schmid B., and Haass C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. 27 (2007) 12413-12418
186. Deng H., Dodson M.W., Huang H., and Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 105 38 (2008) 14503-14508
187. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., and Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
188. Gandhi S., Muqit M.M., Stanyer L., Healy D.G., Abou-Sleiman P.M., Hargreaves I., Heales S., Ganguly M., Parsons L., Lees A.J., Latchman D.S., Holton J.L., Wood N.W., and Revesz T. PINK1 protein in normal human brain and Parkinson's disease. Brain 129 (2006) 1720-1731
189. Silvestri L., Caputo V., Bellacchio E., Atorino L., Dallapiccola B., Valente E.M., and Casari G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet. 14 (2005) 3477-3492
190. Pridgeon J.W., Olzmann J.A., Chin L.S., and Li L. PINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1. PLoS Biol. 5 (2007) e172
191. Zhou C., Huang Y., Shao Y., May J., Prou D., Perier C., Dauer W., Schon E.A., and Przedborski S. The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 12022-12027
192. Valente E.M., Salvi S., Ialongo T., Marongiu R., Elia A.E., Caputo V., Romito L., Albanese A., Dallapiccola B., and Bentivoglio A.R. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56 (2004) 336-341
193. Hatano Y., Sato K., Elibol B., Yoshino H., Yamamura Y., Bonifati V., Shinotoh H., Asahina M., Kobayashi S., Ng A.R., Rosales R.L., Hassin-Baer S., Shinar Y., Lu C.S., Chang H.C., Wu-Chou Y.H., Atac F.B., Kobayashi T., Toda T., Mizuno Y., and Hattori N. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations. Neurology 63 (2004) 1482-1485
194. Abou-Sleiman P.M., Muqit M.M., and Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev., Neurosci. 7 (2006) 207-219
195. Gautier C.A., Kitada T., and Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 11364-11369
196. Kitada T., Pisani A., Porter D.R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E.N., and Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 11441-11446
197. Hoepken H.H., Gispert S., Morales B., Wingerter O., Del Turco D., Mulsch A., Nussbaum R.L., Muller K., Drose S., Brandt U., Deller T., Wirth B., Kudin A.P., Kunz W.S., and Auburger G. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiol. Dis. 25 (2007) 401-411
198. Piccoli C., Sardanelli A., Scrima R., Ripoli M., Quarato G., D'Aprile A., Bellomo F., Scacco S., De Michele G., Filla A., Iuso A., Boffoli D., Capitanio N., and Papa S. Mitochondrial Respiratory Dysfunction in Familiar Parkinsonism Associated with PINK1 Mutation. Neurochem. Res. 33 12 (2008) 2565-2574
199. Petit A., Kawarai T., Paitel E., Sanjo N., Maj M., Scheid M., Chen F., Gu Y., Hasegawa H., Salehi-Rad S., Wang L., Rogaeva E., Fraser P., Robinson B., St George-Hyslop P., and Tandon A. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J. Biol. Chem. 280 (2005) 34025-34032
200. Wang H.L., Chou A.H., Yeh T.H., Li A.H., Chen Y.L., Kuo Y.L., Tsai S.R., and Yu S.T. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiol. Dis. 28 (2007) 216-226
201. Haque M.E., Thomas K.J., D'Souza C., Callaghan S., Kitada T., Slack R.S., Fraser P., Cookson M.R., Tandon A., and Park D.S. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 1716-1721
202. Martins L.M., Morrison A., Klupsch K., Fedele V., Moisoi N., Teismann P., Abuin A., Grau E., Geppert M., Livi G.P., Creasy C.L., Martin A., Hargreaves I., Heales S.J., Okada H., Brandner S., Schulz J.B., Mak T., and Downward J. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol. Cell. Biol. 24 (2004) 9848-9862
203. Yang Y., Ouyang Y., Yang L., Beal M.F., McQuibban A., Vogel H., and Lu B. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 7070-7075
204. Poole A.C., Thomas R.E., Andrews L.A., McBride H.M., Whitworth A.J., and Pallanck L.J. The PINK1/Parkin pathway regulates mitochondrial morphology. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 1638-1643
205. Gomez-Lazaro M., Bonekamp N.A., Galindo M.F., Jordan J., and Schrader M. 6-Hydroxydopamine (6-OHDA) induces Drp1-dependent mitochondrial fragmentation in SH-SY5Y cells. Free Radic. Biol. Med. 44 (2008) 1960-1969
206. Meuer K., Suppanz I.E., Lingor P., Planchamp V., Goricke B., Fichtner L., Braus G.H., Dietz G.P., Jakobs S., Bahr M., and Weishaupt J.H. Cyclin-dependent kinase 5 is an upstream regulator of mitochondrial fission during neuronal apoptosis. Cell Death Differ. 14 (2007) 651-661
207. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
208. Meulener M., Whitworth A.J., Armstrong-Gold C.E., Rizzu P., Heutink P., Wes P.D., Pallanck L.J., and Bonini N.M. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr. Biol. 15 (2005) 1572-1577
209. Lavara-Culebras E., and Paricio N. Drosophila DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits. Gene 400 (2007) 158-165
210. Canet-Aviles R.M., Wilson M.A., Miller D.W., Ahmad R., McLendon C., Bandyopadhyay S., Baptista M.J., Ringe D., Petsko G.A., and Cookson M.R. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9103-9108
211. Kinumi T., Kimata J., Taira T., Ariga H., and Niki E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 317 (2004) 722-728
212. Zhang L., Shimoji M., Thomas B., Moore D.J., Yu S.W., Marupudi N.I., Torp R., Torgner I.A., Ottersen O.P., Dawson T.M., and Dawson V.L. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum. Mol. Genet. 14 (2005) 2063-2073
213. Junn E., Jang W.H., Zhao X., Jeong B.S., and Mouradian M.M. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. J. Neurosci. Res. (2008) doi:10.1002/jnr.21831
214. Andres-Mateos E., Perier C., Zhang L., Blanchard-Fillion B., Greco T.M., Thomas B., Ko H.S., Sasaki M., Ischiropoulos H., Przedborski S., Dawson T.M., and Dawson V.L. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 14807-14812
215. Kim R.H., Smith P.D., Aleyasin H., Hayley S., Mount M.P., Pownall S., Wakeham A., You-Ten A.J., Kalia S.K., Horne P., Westaway D., Lozano A.M., Anisman H., Park D.S., and Mak T.W. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 5215-5220
216. Yang W., Chen L., Ding Y., Zhuang X., and Kang U.J. Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Hum. Mol. Genet. 16 (2007) 2900-2910
217. Lev N., Ickowicz D., Melamed E., and Offen D. Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology 29 (2008) 397-405
218. van der Brug M.P., Blackinton J., Chandran J., Hao L.Y., Lal A., Mazan-Mamczarz K., Martindale J., Xie C., Ahmad R., Thomas K.J., Beilina A., Gibbs J.R., Ding J., Myers A.J., Zhan M., Cai H., Bonini N.M., Gorospe M., and Cookson M.R. RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 10244-10249
219. Tang B., Xiong H., Sun P., Zhang Y., Wang D., Hu Z., Zhu Z., Ma H., Pan Q., Xia J.H., Xia K., and Zhang Z. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum. Mol. Genet. 15 (2006) 1816-1825
220. Moore D.J., Zhang L., Troncoso J., Lee M.K., Hattori N., Mizuno Y., Dawson T.M., and Dawson V.L. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Hum. Mol. Genet. 14 (2005) 71-84
221. Wang D., Qian L., Xiong H., Liu J., Neckameyer W.S., Oldham S., Xia K., Wang J., Bodmer R., and Zhang Z. Antioxidants protect PINK1-dependent dopaminergic neurons in Drosophila. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13520-13525
222. Dodson M.W., and Guo M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr. Opin. Neurobiol. 17 (2007) 331-337
223. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., and Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
224. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., and Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 (2004) 601-607
225. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., and Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16842-16847
226. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., Kolch W., Prokisch H., and Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15 (2006) 223-232
227. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., Kurkinen K., Yu S.W., Savitt J.M., Waldvogel H.J., Faull R.L., Emson P.C., Torp R., Ottersen O.P., Dawson T.M., and Dawson V.L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60 (2006) 557-569
228. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., and Schapira A.H. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann. Neurol. 32 (1992) 782-788